Literature DB >> 19880552

Combined central retinal artery and vein occlusion in a patient with systemic lupus erythematosus and anti-phospholipid syndrome.

P-C Chang1, W-S Chen, H-Y Lin, H-M Lee, S-J Chen.   

Abstract

Combined central retinal artery occlusion and central retinal venous occlusion have been rarely reported in patients with systemic lupus erythematosus and anti-phospholipid syndrome. The impact of this severe vaso-occlusive disease on vision is usually devastating and permanent in spite of vigorous treatment. We report herein a 35-year-old female patient displaying a transient and reversible process. Her best-corrected visual acuity improved from 6/60 to 6/8.6 1 day later, before the initiation of systemic corticosteroid and anticoagulant treatment. The retina regained a normal appearance with her vision recovering to 6/6 2 weeks after the episode of temporary vision loss. Her rapid recovery suggests that continued anti-coagulation therapy and close follow-up to prevent severe complications and recurrent thrombosis is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880552     DOI: 10.1177/0961203309345751

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

1.  Intravitreal bevacizumab for severe vaso-occlusive retinopathy in systemic lupus erythematosus.

Authors:  Won June Lee; Hee Yoon Cho; Yoon Jung Lee; Byung Ro Lee; Jae Pil Shin
Journal:  Rheumatol Int       Date:  2011-09-28       Impact factor: 2.631

2.  Clinical Features of Combined Central Retinal Artery and Vein Occlusion.

Authors:  Hao Wang; Yongye Chang; Fen Zhang; Rong Yang; Suxia Yan; Jieying Dong; Minglian Zhang; Shaomin Peng
Journal:  J Ophthalmol       Date:  2019-10-09       Impact factor: 1.909

3.  Severe Vaso-Occlusive Retinopathy in Systemic Lupus Erythematosus: A Case Series.

Authors:  Kshitiz Kumar; Shouvick Dan; Tushar K Sinha; Debashish Bhattacharya
Journal:  Cureus       Date:  2021-01-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.